ISM-012042 is under clinical development by InSilico Medicine and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase I drugs for Inflammatory Bowel Disease have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ISM-012042’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ISM-012042 overview
ISM012-042 is under development for the treatment of inflammatory bowel disease (IBD). It acts by targeting prolyl hydroxylase domain 1 and 2 (PHD1 and 2) and is being developed based on Chemistry42 artificial intelligence (AI) platform. It is administered through oral route.
InSilico Medicine overview
InSilico Medicine (InSilico) is an artificial intelligence-driven pharma-technology company that focuses on accelerating drug discovery and development. It provides integrated drug discovery software suite products including pandaOmics, generative biologics, multi-omics target discovery and deep biology analysis engine to discover novel targets. The company offers chemistry 42, a machine learning de-novo drug design engineering platform to generate novel molecules and Inclinico, to design and predict clinical trials. InSilico works in collaboration with pharmaceutical companies to develop drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s disease, Alzheimer’s disease, diabetes, sarcopenia, aging and others. It operates in Hong Kong and the US. InSilico is headquartered in Hong Kong.
For a complete picture of ISM-012042’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
